Saranas raises $2.8M to pilot its internal bleeding detector

Saranas Early Bird
Saranas' Early Bird device includes a sheath embedded with sensors to detect bleeding from accidental injuries during endovascular procedures such as transcatheter aortic valve replacements, where the femoral artery is used to obtain access. (Saranas)

Saranas has raised $2.8 million in new financing to support commercialization and a multicenter clinical pilot of its internal bleeding monitoring system, which it recently submitted to the FDA for de novo classification.

The company’s Early Bird medical device includes a vascular access sheath embedded with sensors that can detect bleeding from a blood vessel accidentally injured during endovascular procedures, such as transcatheter aortic valve replacements, large-bore hemodynamic support placements or other complex interventions where the femoral artery or vein is used for access.

Since its last financing round, Saranas has completed design verification and validation work, said President and CEO Zaffer Syed in a statement following the series C funding closure. The Early Bird technology was invented at the Texas Heart Institute.

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.

In addition, the company’s submission to the FDA incorporated agency recommendations in the presubmission process, following biocompatibility and preclinical animal studies, Syed said.

“We continue our work to deliver a product to market that has the potential to significantly reduce bleeding complications while reducing related costs to providers and the healthcare system,” he said. According to the Houston-based company, over 20 million U.S. patients require vascular access procedures, with 1 million experiencing life-threatening bleeding complications.

In 2015, Saranas raised $4.5 million in equity to develop the sheath, which detects injuries in real-time by measuring differences in electrical resistance across the blood vessel following a rupture.